Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
2003 1
2007 1
2009 2
2010 5
2011 4
2012 5
2013 11
2014 9
2015 11
2016 21
2017 29
2018 20
2019 21
2020 38
2021 31
2022 26
2023 33
2024 33
2025 47
2026 37

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?
Villablanca EJ, Selin K, Hedin CRH. Villablanca EJ, et al. Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):493-507. doi: 10.1038/s41575-022-00604-y. Epub 2022 Apr 19. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35440774 Review.
The absence of treatments that directly promote mucosal healing and regeneration in IBD could be linked to the lack of understanding of the underlying pathways. The range of potential strategies to achieve mucosal healing is diverse. Howe …
The absence of treatments that directly promote mucosal healing and regeneration in IBD could be linked to the l …
Treatment of Inflammatory Bowel Disease: A Comprehensive Review.
Cai Z, Wang S, Li J. Cai Z, et al. Front Med (Lausanne). 2021 Dec 20;8:765474. doi: 10.3389/fmed.2021.765474. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34988090 Free PMC article. Review.
However, a considerable fraction of patients do not respond to available treatments or lose response, which calls for new therapeutic strategies. Diverse therapeutic options are emerging, involving small molecules, apheresis therapy, improved intestinal microecology …
However, a considerable fraction of patients do not respond to available treatments or lose response, which calls for new therapeutic …
Macrophages in intestinal homeostasis and inflammatory bowel disease.
Hegarty LM, Jones GR, Bain CC. Hegarty LM, et al. Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):538-553. doi: 10.1038/s41575-023-00769-0. Epub 2023 Apr 17. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37069320 Review.
Macrophages are essential for the maintenance of intestinal homeostasis, yet appear to be drivers of inflammation in the context of inflammatory bowel disease (IBD). How these peacekeepers become powerful aggressors in IBD is still unclear, but technological advance …
Macrophages are essential for the maintenance of intestinal homeostasis, yet appear to be drivers of inflammation in the context of inflamma …
Understanding the therapeutic toolkit for inflammatory bowel disease.
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, Danese S. Vieujean S, et al. Nat Rev Gastroenterol Hepatol. 2025 Jun;22(6):371-394. doi: 10.1038/s41575-024-01035-7. Epub 2025 Jan 31. Nat Rev Gastroenterol Hepatol. 2025. PMID: 39891014 Review.
A treat-to-target approach is recommended, involving iterative treatment adjustments to achieve clinical response, reduce inflammatory markers and achieve long-term goals such as mucosal healing. ...Additionally, the importance of a multidisciplinary t …
A treat-to-target approach is recommended, involving iterative treatment adjustments to achieve clinical response, reduce infl …
Key Interleukins in Inflammatory Bowel Disease-A Review of Recent Studies.
Aebisher D, Bartusik-Aebisher D, Przygórzewska A, Oleś P, Woźnicki P, Kawczyk-Krupka A. Aebisher D, et al. Int J Mol Sci. 2024 Dec 26;26(1):121. doi: 10.3390/ijms26010121. Int J Mol Sci. 2024. PMID: 39795980 Free PMC article. Review.
In the treatment of patients with IBD, the current therapeutic target is mucosal healing, as intestinal inflammation often persists despite resolution of abdominal symptoms. ...Interleukins are one of the molecular targets in IBD …
In the treatment of patients with IBD, the current therapeutic target is mucosal healing, as intestinal i …
TL1A as a Target in Inflammatory Bowel Disease: Exploring Mechanisms and Therapeutic Potential.
Tettoni E, Gabbiadini R, Dal Buono A, Privitera G, Vadalà V, Migliorisi G, Bertoli P, Quadarella A, Bezzio C, Armuzzi A. Tettoni E, et al. Int J Mol Sci. 2025 May 23;26(11):5017. doi: 10.3390/ijms26115017. Int J Mol Sci. 2025. PMID: 40507829 Free PMC article. Review.
Tumor necrosis factor-like ligand 1A (TL1A) has emerged as a promising new target for IBD treatment, due to its dual role in inflammatory and fibrotic pathways. TL1A, acting through its receptor death receptor 3 (DR3), orchestrates mucosal inflammation …
Tumor necrosis factor-like ligand 1A (TL1A) has emerged as a promising new target for IBD treatment, due to its dual ro …
Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles: A focus on inflammatory bowel disease.
Clua-Ferré L, Suau R, Vañó-Segarra I, Ginés I, Serena C, Manyé J. Clua-Ferré L, et al. Clin Transl Med. 2024 Nov;14(11):e70075. doi: 10.1002/ctm2.70075. Clin Transl Med. 2024. PMID: 39488745 Free PMC article. Review.
MAIN TOPICS COVERED: This review aims to provide a comprehensive examination of the therapeutic efficacy of MSC-EVs in IBD, with a focus on their mechanisms of action and potential impact on treatment outcomes. ...They also promote mucosal healing and …
MAIN TOPICS COVERED: This review aims to provide a comprehensive examination of the therapeutic efficacy of MSC-EVs in IBD, with a fo …
Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases.
Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Hou Q, et al. Front Immunol. 2021 Jan 20;11:623691. doi: 10.3389/fimmu.2020.623691. eCollection 2020. Front Immunol. 2021. PMID: 33584726 Free PMC article. Review.
The continuous renewal and repair of intestinal mucosal epithelium after injury depend on ISCs. Inflamed mucosa healing could be a new target for the improvement of clinical symptoms, disease recurrence, and resection-free survival in IBD treated patie …
The continuous renewal and repair of intestinal mucosal epithelium after injury depend on ISCs. Inflamed mucosa healing could …
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
BACKGROUND: A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. ...FINDINGS: 498 patients received standard induc …
BACKGROUND: A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clini …
Diagnose und Monitoring bei chronisch-entzündlicher Darmerkrankung.
Ansprenger C, Burri E. Ansprenger C, et al. Ther Umsch. 2019 Jan;75(5):316-328. doi: 10.1024/0040-5930/a001002. Ther Umsch. 2019. PMID: 30700246 Review. German.
No single feature establishes the diagnosis alone. In recent years, therapeutic goals in IBD have evolved from clinical endpoints to endoscopic or even histologic targets. However, these targets, e. g. mucosal healing, still have to be uniformly …
No single feature establishes the diagnosis alone. In recent years, therapeutic goals in IBD have evolved from clinical endpoints to …
339 results